Cybin Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CYBN NYSE American 2834 www.cybin.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cybin Inc.

Cybin Granted Key Patent for CYB004 DMT Program, Supports GAD Treatment Development - Jun 25th, 2025 2:08 am
Trump Trade: President said to weigh possible U.S. strike against Iran - Jun 19th, 2025 8:10 am
Psychedelic advocates hopeful Trump administration will support space, STAT says - Jun 19th, 2025 7:26 am
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 - Jun 18th, 2025 6:30 am
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - Jun 13th, 2025 5:45 am
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference - Jun 12th, 2025 5:30 am
Cybin to Participate in the 2025 Psychedelic Science Conference - Jun 11th, 2025 5:30 am
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder - Jun 3rd, 2025 5:30 am
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 - May 22nd, 2025 5:30 am
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - May 20th, 2025 5:30 am
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder - May 15th, 2025 5:30 am
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase - May 14th, 2025 5:30 am
Psychedelic: Compass, GH Research, MindMed report quarterly earnings - May 9th, 2025 9:11 am
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder - May 8th, 2025 5:30 am
Cybin to Participate at the 28th Annual Milken Institute Global Conference - May 1st, 2025 5:30 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Apr 27th, 2025 1:31 pm
Psychedelic: Clearmind completes clinical site initiations for AUD trial - Apr 25th, 2025 9:30 am
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Apr 23rd, 2025 5:30 am
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs - Apr 21st, 2025 6:00 am
Psychedelic: Exclusive talk with biotech company Clearmind Medicine - Mar 22nd, 2025 8:30 am